Education
About Us
Working with TipRanks
Follow Us
Harvard Bioscience (HBIO)
NASDAQ:HBIO
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-6.05Last Year’s EPS
-0.1Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call conveyed a cautiously optimistic tone: management highlighted meaningful operational and financial improvements (margin expansion, adjusted EBITDA growth, refinancing, manufacturing consolidation, stronger cash flow, remediation of controls, and clear strategic priorities toward translational science and higher-margin NPIs). However, notable headwinds remain — full-year revenue declined 8% YoY, a large goodwill impairment drove a substantial GAAP loss, regional softness (Europe, Americas), dependence on NIH timing and tariff risk, and near-term EBITDA pressure from reinstated compensation. Guidance for modest revenue growth (2%–4%) and mid-single to high-single-digit adjusted EBITDA growth (6%–10%) indicates management expects recovery to continue but not a dramatic turnaround in 2026.Company Guidance
Fourth Quarter Revenue Above Midpoint of Guidance
Q4 revenue of $23.7M was just above the midpoint of guidance ($22.5M–$24.5M) and represented sequential revenue growth of 15%.
Significant Margin Improvement in Q4
Q4 gross margin of ~59.7% (reported as 60% at the high end of guidance) improved by ~260 basis points from 57.1% in Q4 2024 — the highest gross margin in the last seven quarters.
Strong Adjusted EBITDA Performance
Q4 adjusted EBITDA was $3.8M, up 27% year-over-year. Full-year adjusted EBITDA was $8.1M, up 12.5% from $7.2M in 2024.
Improved Cash Flow and Deleveraging Progress
Cash flow from operations improved to $6.7M (vs. $1.4M at end of 2024) and net debt declined by $1.8M to $31.4M, reflecting debt repayments and refinancing liquidity.
Completed Refinancing and Reduced Debt Service
Completed a comprehensive refinancing that extended debt maturities and reduced annual debt service to $5M, generating approximately $3M in annual cash savings in the near term and enhancing financial flexibility.
Manufacturing Consolidation to Drive Future Savings
Announced phased closure of Holliston and consolidation into Minneapolis and European centers of excellence expected to generate $3M of savings in 2027 and $4M annually thereafter.
Strategic Moves: Governance, Leadership and Controls
Strengthened governance with four new board members, appointment of a product/Scientific Advisory Board, and permanent CFO appointment; remediated material weaknesses and one significant deficiency — signaling stronger controls.
Clear Strategic Focus and NPI Tailwinds
Shifting toward translational science and higher-margin platform products (SoHo telemetry, BTX for bioproduction, Mesh MEA, Incub8). Management expects BTX and Mesh MEA to grow in double digits in 2026 and reiterated a goal to expand consumables/recurring revenue (currently ~55% recurring).
Backlog and Regional Momentum
Ended the year with the highest backlog in over two years. China & Asia Pacific saw Q4 revenue up ~10% YoY (catch-up orders), and management expects Asia cadence to normalize absent tariff changes.
Forward Guidance for 2026
Introduced FY2026 guidance: revenue growth of 2%–4%, gross margin of 58%–60%, and adjusted EBITDA growth of 6%–10%. Q1 2026 guidance: revenue $20M–$22M, adjusted gross margin 57%–59%, adjusted EBITDA $1M–$2.2M.
HBIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HBIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 12, 2026 | $0.51 | $0.49 | -2.56% |
Nov 06, 2025 | $0.59 | $0.55 | -7.31% |
Aug 11, 2025 | $0.53 | $0.48 | -9.11% |
May 12, 2025 | $0.32 | $0.35 | +11.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Harvard Bioscience (HBIO) report earnings?
Harvard Bioscience (HBIO) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Harvard Bioscience (HBIO) earnings time?
Harvard Bioscience (HBIO) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HBIO EPS forecast?
HBIO EPS forecast for the fiscal quarter 2026 (Q1) is -6.05.